Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xin-Qiao Zhang
Observed name:
Xin-qiao Zhang
Institution:
The University of Texas MD Anderson Cancer Center
Observed institutions:
The University of Texas MD Anderson Cancer Center,
Kyushu University
OpenAlex ID:
A5061394396
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
2007
·
Daniel H. Sterman
, Adri Recio
, et al.
·
Clinical Cancer Research
·
157
Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer
2002
·
Motoyuki Yamashita
, Charles J Rosser
, et al.
·
Cancer Gene Therapy
·
74
A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers
2016
·
Arlene Siefker-Radtke
, Xin-qiao Zhang
, et al.
·
Molecular Therapy
·
64
PDF
Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma CellsIn vitroandIn vivo
2008
·
Kathleen F. Pirollo
, Antonina Rait
, et al.
·
Clinical Cancer Research
·
56
PDF
Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53–induced apoptosis
2008
·
Akira Nakamizo
, Toshiyuko Amano
, et al.
·
Neuro-Oncology
·
32
PDF
Abstract 385: MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma
2019
·
Jianfeng Chen
, Omar Alhalabi
, et al.
·
Cancer Research
·
1
72. A Phase l Study of RB94 in Genitourinary Cancers Using a Tumor-Targeted Systemic Nanodelivery System
2016
·
Arlene Siefker-Radtke
, Xin-qiao Zhang
, et al.
·
Molecular Therapy
·
1
PDF
Abstract 385: MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma
2019
·
Jianfeng Chen
, Omar Alhalabi
, et al.
·
Experimental and Molecular Therapeutics
Abstract CT059: Systemic administration using targeted gene delivery with SGT-RB94 shows evidence of tumor targeting and anticancer activity: a phase I first-in-man trial
2016
·
Arlene Siefker-Radtke
, Xin-qiao Zhang
, et al.
·
Cancer Research
A modified p53 adenoviral vector is more potent than wild-type p53 in bladder cancer cells
2004
·
William F. Benedict
, Xin-Qiao Zhang
, et al.
·
Cancer Research
Show more works
View as search
Works count:
10
Citation count:
385
H-index:
5
I10-index:
5
Year
Topic
Type